Merck KGaA is in the investment-grade market Tuesday, a day after holding investor calls, to help fund its $3.9 billion ...

Immunome's varegacestat shows promising efficacy in desmoid tumors, with phase 3 topline data expected by 2025-end. Read why ...

Shares of SpringWorks Therapeutics SWTX have rallied 32.9% in the past three months compared with the industry’s increase of 2.7%. Here, we discuss the reasons for the same. Strong Launch of ...

Shares of SpringWorks Therapeutics, Inc. SWTX have rallied 81% in the past three months compared with the industry’s increase of 15.9%. In November 2023, the FDA approved SpringWorks’ oral ...

SpringWorks Therapeutics’ SWTX oral gamma-secretase inhibitor, Ogsiveo (nirogacestat), was approved by the FDA for treating adult patients with progressing desmoid tumors in November 2023.

SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for patients living with ...

BofA lowered the firm’s price target on SpringWorks Therapeutics (SWTX) to $55 from $58 and keeps a Buy rating on the shares. While political and rate uncertainty continues to be an overhang ...

SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient ...

SpringWorks Therapeutics has received FDA approval for Nirogacestat, marking its entry into the commercial stage biotech industry. Read more on SWTX stock here.

SpringWorks launched last year with $103 million in financing, led by Bain Capital, OrbiMed Advisors and Pfizer Inc., and a plan to develop treatments for patients who lack good treatment options.